SCHEMBL336233

SCHEMBL336233

Cc1cc(CO)cnc1C#N

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.35
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35
AR P10275 5/20 0.35
NSD2 O96028 1/20 0.34
CTSC P53634 1/20 0.32
SHBG P04278 1/20 0.32
POLB P06746 2/20 0.31
FYN P06241 1/20 0.31
HSD17B10 Q99714 1/20 0.31
HPGD P15428 1/20 0.31
CHEK1 O14757 1/20 0.31
JAK2 O60674 1/20 0.31
JAK1 P23458 1/20 0.31
PIK3CD O00329 1/20 0.30
GRM5 P41594 1/20 0.30
KDM4E B2RXH2 1/20 0.30
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12524698 0.83 CYP2A6 (0.36) CYP2A6CTSCPOLBHPGDPIK3CD
SCHEMBL335184 0.78 ALDH1A1 (0.41) CYP11B1CYP11B2ARPOLBCHEK1
SCHEMBL26075542 0.78 CYP11B1 (0.35) CYP11B1CYP11B2POLBCHEK1PIK3CD
SCHEMBL12248183 0.77 NPC1 (0.43) CYP11B1CYP11B2ARPOLBFYN
SCHEMBL362107 0.75 CHEK1 (0.37) ARPOLBHPGDCHEK1JAK2
SCHEMBL336161 0.74 SHBG (0.41) CYP2A6SHBGFYNHSD17B10HPGD
SCHEMBL4918585 0.74 NOS3 (0.46) CYP2A6CYP11B1CYP11B2POLBJAK2
SCHEMBL26503375 0.74 CYP11B1 (0.33) CYP11B1CYP11B2
SCHEMBL19251508 0.72 KDM4E (0.33) POLBJAK2JAK1PIK3CDKDM4E
SCHEMBL12941448 0.72 HTT (0.42) CYP2A6CYP11B1CYP11B2PIK3CDGRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2300476-B1 TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS GLAXO GROUP LTD (GB) 2014-01-08 EP disclosed
EP-2300476-B1 TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS GLAXO GROUP LTD (GB) 2014-01-08 EP disclosed
US-8097628-B2 Compounds GLAXO GROUP LIMITED (GB) 2012-01-17 US disclosed
US-8097628-B2 Compounds GLAXO GROUP LIMITED (GB) 2012-01-17 US disclosed
US-8097628-B2 Compounds GLAXO GROUP LIMITED (GB) 2012-01-17 US disclosed
EP-2300476-A1 TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS Glaxo Group Limited (GB) 2011-03-30 EP disclosed
US-20090306089-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2009-12-10 US disclosed
US-20090306089-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2009-12-10 US disclosed
US-20090306089-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2009-12-10 US disclosed
WO-2009141398-A1 TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS GLAXO GROUP LIMITED (GB) 2009-11-26 WO disclosed
WO-2009141398-A1 TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS GLAXO GROUP LIMITED (GB) 2009-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306089-A1 COMPOUNDS SDHA, NQO1, SDHB CYP2A6 238/4885CYP11B1 7/4885CYP11B2 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.